>
HUTCHMED China logo

HCM - HUTCHMED China Share Price

391p -1.0  -0.3%

Last Trade - 05/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £2.92bn
Enterprise Value £2.66bn
Revenue £164.2m
Position in Universe 253rd / 1819
Bullish
Bearish
Unlock HCM Revenue
Momentum
Relative Strength (%)
1m -5.24%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
178.2 216.1 241.2 214.1 204.9 228 330.3 470.7 +5.0%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, HUTCHMEDChina Ltd revenues increased 11% to $228M. Net lossincreased 19% to $125.7M. Revenues reflect Goods -thirdparties increase of 16% to $203.6M, Revenue fromBusiness-Related Activities increase of 45% to $3.7M.Higher net loss reflects Unallocated segment loss increaseof 6% to $18.2M. Basic Earnings per Share excludingExtraordinary Items decreased from -$0.16 to -$0.18.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for HCM
Graphical History

Revenue

HCM Revenue Unlock HCM Revenue

Net Income

HCM Net Income Unlock HCM Revenue

Normalised EPS

HCM Normalised EPS Unlock HCM Revenue

PE Ratio Range

HCM PE Ratio Range Unlock HCM Revenue

Dividend Yield Range

HCM Dividend Yield Range Unlock HCM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
HCM EPS Forecasts Unlock HCM Revenue
Profile Summary

Hutchison China Meditech Limited is an investment holding company principally engaged in the manufacture and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Manufacturing Business segment is engaged in the manufacture and distribution of drug products. The Distribution Business segment provides sales and marketing services to pharmaceutical manufacturers. The Company's products include prescription and over the counter (OTC) pharmaceuticals such as banlangen, fu fang dan shen tablets and shexiang baoxin pills and others, and consumer health products. In addition, the Company also develops targeted therapeutics and immunotherapies for oncology and autoimmune diseases.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 18, 2000
Public Since May 19, 2006
No. of Shareholders: n/a
No. of Employees: 1,280
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , FTSE Aim 100 ,
Exchange London Stock Exchange (AIM)
Shares in Issue 744,515,660
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HCM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HCM
Upcoming Events for HCM
Frequently Asked Questions for HUTCHMED China
What is the HUTCHMED China share price?

As of 05/05/21, shares in HUTCHMED China are trading at 391p, giving the company a market capitalisation of £2.92bn. This share price information is delayed by 15 minutes.

How has the HUTCHMED China share price performed this year?

Shares in HUTCHMED China are currently trading at 391p and the price has moved by 14.29% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the HUTCHMED China price has moved by -7.46% over the past year.

What are the analyst and broker recommendations for HUTCHMED China?

Of the analysts with advisory recommendations for HUTCHMED China, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for HUTCHMED China is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will HUTCHMED China next release its financial results?

HUTCHMED China is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the HUTCHMED China dividend yield?

HUTCHMED China does not currently pay a dividend.

Does HUTCHMED China pay a dividend?

HUTCHMED China does not currently pay a dividend.

When does HUTCHMED China next pay dividends?

HUTCHMED China does not currently pay a dividend.

How do I buy HUTCHMED China shares?

To buy shares in HUTCHMED China you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of HUTCHMED China?

Shares in HUTCHMED China are currently trading at 391p, giving the company a market capitalisation of £2.92bn.

Where are HUTCHMED China shares listed? Where are HUTCHMED China shares listed?

Here are the trading details for HUTCHMED China:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: HCM
What kind of share is HUTCHMED China?

Based on an overall assessment of its quality, value and momentum, HUTCHMED China is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a HUTCHMED China share price forecast 2021?

Shares in HUTCHMED China are currently priced at 391p. At that level they are trading at 58.74% discount to the analyst consensus target price of 947.65.

Analysts covering HUTCHMED China currently have a consensus Earnings Per Share (EPS) forecast of -0.531 for the next financial year.

How can I tell whether the HUTCHMED China share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like HUTCHMED China. Over the past six months, the relative strength of its shares against the market has been -35.31%. At the current price of 391p, shares in HUTCHMED China are trading at -14.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the HUTCHMED China PE Ratio?

We were not able to find PE ratio data for HUTCHMED China.

Who are the key directors of HUTCHMED China?

HUTCHMED China's management team is headed by:

Simon To - CHM
Christian Hogg - CEO
Edith Shih - SEC
Chig Fung Cheng - CFO
Dan Eldar - NED
Paul Carter - NID
Karen Ferrante - NID
Graeme Jack - NID
Weiguo Su - CSO
Shu Kam Mok - NID
May Wang - SVP
Zhenping Wu - SVP
Mark Lee - SVF
Who are the major shareholders of HUTCHMED China?

Here are the top five shareholders of HUTCHMED China based on the size of their shareholding:

Hutchison Healthcare Holdings Ltd. Holding Company
Percentage owned: 44.66% (332.5m shares)
Capital International Investors Investment Advisor
Percentage owned: 7.11% (53.0m shares)
Mitsui & Co Ltd Corporation
Percentage owned: 2.79% (20.7m shares)
General Atlantic LLC Private Equity
Percentage owned: 2.69% (20.0m shares)
Hogg (Christian) Individual Investor
Percentage owned: 1.47% (10.9m shares)
Similar to HCM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.